Alnylam Pharmaceuticals Inc (ALNY)vsModerna Inc (MRNA)
ALNY
Alnylam Pharmaceuticals Inc
$205.48
-28.31%
HEALTHCARE · Cap: $35.71B
MRNA
Moderna Inc
$54.49
-2.36%
HEALTHCARE · Cap: $24.53B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 93% more annual revenue ($4.29B vs $2.23B). ALNY leads profitability with a 12.6% profit margin vs -143.5%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
MRNA
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.2%
Fair Value
$2337.47
Current Price
$205.48
$2131.99 discount
Margin of Safety
+70.5%
Fair Value
$137.40
Current Price
$54.49
$82.91 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Revenue surging 260.2% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 25.5x book value
Weak financial health signals
ROE of -43.1% — below average capital efficiency
Earnings declined 85.1%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.49 suggests the stock is reasonably priced for its growth.
Bull Case : MRNA
The strongest argument for MRNA centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 260.2% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 67.0x leaves little room for execution misses.
Bear Case : MRNA
The primary concerns for MRNA are Piotroski F-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ALNY profiles as a growth stock while MRNA is a hypergrowth play — different risk/reward profiles.
MRNA carries more volatility with a beta of 0.94 — expect wider price swings.
MRNA is growing revenue faster at 260.2% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 32/100) and 96.4% revenue growth. MRNA offers better value entry with a 70.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?